Phaseline

Companies › Pieris Pharmaceuticals

Pieris Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cinrebafusp alfa (PRS-343)
HER2/4-1BB bispecific antibody
ERBB2, TNFRSF9Phase 2HER2-positive Gastric Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05190445Cinrebafusp alfa (PRS-343)Phase 2HER2-positive Gastric CancerOncologyFeb 2023

Targets

ERBB2 (1) TNFRSF9 (1)

Companies with the same targets

Beijing Biotech Roche Pfizer Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Suzhou Suncadia Biopharmaceuticals Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Yuhan

Companies built like this

Lyvgen Biopharma Holdings Vasgene Therapeutics Suzhou BlueHorse Therapeutics Evaxion Biotech Primmune Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.